ArticleNature communications2021
Tumour gene expression signature in primary melanoma predicts long-term outcomes.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 65 citations in OpenAlex.
- Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.Nature communications · 2024Trial
- The melanocytic transcriptomic state is independently associated with poor overall survival in patients with metastatic melanoma.Science advances · 2026Article
- Review
- Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.Nature communications · 2026Article
- Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.Cancers · 2026Review
- CD38Frontiers in oncology · 2026Article
- Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.Hepatic oncology · 2025Review
- Multi-Modal Biomarker Profiling of Tumor Microenvironment and Genomic Alterations to Enhance Immunotherapy Stratification in Melanoma.Current issues in molecular biology · 2025Article
- Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning.NPJ precision oncology · 2025Article
- AnInternational journal of molecular sciences · 2025Article
- Integrated Analysis of Single-Cell and Bulk RNA Data Reveals Complexity and Significance of the Melanoma Interactome.Cancers · 2025Article
- The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma.European journal of epidemiology · 2025Article
- Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.Liver cancer · 2024Article
- RNA-seq validation of microRNA expression signatures for precision melanoma diagnosis and prognostic stratification.BMC medical genomics · 2024Article
- Clarifying new molecular subtyping and precise treatment of melanoma based on disulfidptosis-related lncRNA signature.European journal of medical research · 2024Article
- Establishment of a CD8+ T cells-related prognostic risk model for acral melanoma based on single-cell and bulk RNA sequencing.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Probabilistic pathway-based multimodal factor analysis.Bioinformatics (Oxford, England) · 2024Article
- Gene Expression Profile of Benign, Intermediate, and Malignant Spitz and Spitzoid Melanocytic Lesions.Cancers · 2024Article
- DNA-based molecular classifiers for the profiling of gene expression signatures.Journal of nanobiotechnology · 2024Article
- Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.Annals of surgical oncology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
26 authors at 10 institutions in 5 countries.
Manik GargEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0003-0453-2058
Dominique-Laurent CouturierCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK.ORCID http://orcid.org/0000-0001-5774-5036
Jérémie NsengimanaUniversity of Leeds School of Medicine, Leeds, United Kingdom.ORCID http://orcid.org/0000-0002-3603-4208
Nuno A FonsecaCIBIO/InBIO-Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Rua Padre Armando Quintas, 4485-601, Vairão, Portugal.ORCID http://orcid.org/0000-0003-4832-578X
Matthew WongchenkoOncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-1230-7117
Yibing YanOncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Martin LaussLund University Cancer Center, Lund University, Lund, Sweden.
Göran B JönssonLund University Cancer Center, Lund University, Lund, Sweden.
Julia Newton-BishopUniversity of Leeds School of Medicine, Leeds, United Kingdom.
Christine ParkinsonCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mark R MiddletonOxford NIHR Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0167-1685
D Timothy BishopUniversity of Leeds School of Medicine, Leeds, United Kingdom.ORCID http://orcid.org/0000-0002-8752-8785
Sarah McDonaldDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Nikki StefanosDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
John TadrossDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID http://orcid.org/0000-0002-8424-1252
Ismael A VergaraMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-2960-2967
Serigne LoMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-5092-5544
Felicity NewellQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0003-0469-2705
James S WilmottMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
John F ThompsonMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-2816-2496
Georgina V LongMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Pippa CorrieCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
David J Adams *Experimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0001-9490-0306
Alvis Brazma *European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0001-5988-7409
Roy Rabbie *Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. rr13@sanger.ac.uk.ORCID http://orcid.org/0000-0002-9195-5659
Cambridge University Hospitals NHS Foundation Trust · GBThe University of Sydney · AUUniversity of Leeds · GBEuropean Bioinformatics Institute · GBLund University · SEQIMR Berghofer Medical Research Institute · AUUniversidade do Porto · PTUniversity of Cambridge · GBUniversity of Oxford · GBWellcome Sanger Institute · GB
Funding
Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0MCancer Research UK 19167Cancer Research UK 8466Cancer Research UK C588/A10721Cancer Research UK C588/A19167Cancer Research UK C8216/A6129Department of HealthNCI NIH HHS R01 CA083115Wellcome Trust
Abstract
Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary tumours from 204 RNA-sequenced melanomas within a large adjuvant trial, identifying a 121 metastasis-associated gene signature. This signature strongly associated with progression-free (HR = 1.63, p = 5.24 × 10
Indexed as
Gene Expression ProfilingGene Expression Regulation, NeoplasticDatabases, GeneticHumansMachine LearningMelanomaMultivariate AnalysisNeoplasm StagingPrognosisProgression-Free SurvivalProportional Hazards ModelsReproducibility of ResultsTime FactorsTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.